Analysts Viewpoint
Understanding the Risks of Investing in Bioline Rx Ltd ADR (BLRX)
As this happened, Maxim Group upgraded its Bioline Rx Ltd ADR [BLRX] rating to a Buy from a a Hold
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.